Funding is key to bringing the neuroprotective drug ApTOLL to market and providing a new therapeutic option for the patients.

More than 400 students interested in acquiring knowledge and skills that will allow them to dedicate themselves to research aimed at finding solutions to people's health problems have already passed through the Master.

The BEACON clinical trial, in which Vall d'Hebron participates, has observed that adding Bevacizumab to treatment with different chemotherapy drugs reduces tumor size in a greater number of patients.

In total, different projects of six research groups will be promoted, focusing on precision medicine and advanced therapies.

Phase IV AI is included in the Horizon Europe programme, lasts 3 years and prioritises data security and privacy compliance.

Dr. Carmen Espejo and Dr. Georgina Arrambide, researchers at Cemcat and Vall d'Hebron Research Institute, are the first authors of the article.

These are the results of a study published in Nature Communications and led by the Vall d'Hebron Research Institute (VHIR), the University of Lleida (UdL) and the Biomedical Research Institute of Lleida (IRBLleida).

One study will improve the transition process of adolescents and, the other, will detect the risk of deterioration in hospitalised patients.

The research findings propose to modify the McDonald 2017 criteria, only in those in whom diagnosis using the current criteria is not possible.

The meeting, held between November 29 and December 2 in Barcelona, brought together experts and opinion leaders in the field of multiple sclerosis from around the world.

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

The study, which is part of the European RECOMB project, is currently recruiting volunteers.

The grant program offers young researchers the opportunity to further their training in the field of multiple sclerosis.

During the last year, the collaboration between Vall d’Hebron and ZeClinics has found three nanobody candidates with potent anticancer properties in zebrafish model.

This clinical trial is part of the European project RBDCOV, led by HIPRA in which Vall d'Hebron participates, whose recruitment is still open.

The meeting has been the meeting point of the EpSSG group dedicated to research to improve the treatment of childhood and adolescent soft tissue sarcomas.

‘RBDCOV Talks' brings vaccine clinical research closer to the general audience through a podcast series with 10 scientists, clinicians, specialists and community advocates who are partners in the project.

Research led by the doctor has stopped unnecessary medicalisation with aspirin during pregnancy.

The product is now in the last stage of prototyping and will move to the verification and validation stages thanks to current fundraising.

The event included several oral presentations by internal researchers and the traditional poster competition.

More than 200 people have participated in a day full of short talks, conferences, and networking activities.

A project to develop a compact, inexpensive and easy to use device for mass screening for malaria.

This collaboration solidifies their co-ownership of the patent application for "markers for the diagnosis of large vessel occlusion"

This investment from EIT Health in the project will enable D-Sight to progress in the clinical development of its groundbreaking treatment for the early stages of diabetic retinopathy.